Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. (NASDAQ: BYSI) generates a steady flow of news centered on the clinical and regulatory progress of its lead asset, Plinabulin, and on its corporate and financing activities. As a clinical-stage biopharmaceutical company focused on cancer, BeyondSpring’s updates often highlight new data from phase 2 and phase 3 trials in non-small cell lung cancer (NSCLC) and other tumor types, as well as mechanistic findings related to Plinabulin’s dendritic cell maturation and immune-modulating properties.
News releases frequently cover results from major oncology conferences and journals. Examples include presentations at the American Society of Clinical Oncology (ASCO), the IASLC/ASCO North America Conference on Lung Cancer (NACLC), the Society for Immunotherapy of Cancer (SITC), Immuno-Oncology 360°, and ESMO Asia, along with peer-reviewed publications in outlets such as Lancet Respiratory Medicine and Med (Cell Press). These communications describe outcomes from the DUBLIN‑3 phase 3 trial, the 303 and 302 phase 2 studies, and basket trials combining Plinabulin with checkpoint inhibitors, chemotherapy, and radiation.
Investors following BYSI news can also expect regular financial updates, including quarterly results, cash position, and operating expense trends, as well as 10‑K filing announcements. Corporate news items address equity financings, such as registered offerings of ordinary shares, and strategic transactions involving BeyondSpring’s equity stake in SEED Therapeutics, a targeted protein degradation company co-founded by BeyondSpring.
For market participants tracking oncology pipelines, the BYSI news stream provides insight into Plinabulin’s clinical performance, safety profile, biomarker research, and planned registrational strategies, including the company’s intention to advance confirmatory trials like DUBLIN‑4. Bookmarking the news page allows readers to monitor how new data, conference presentations, and SEC-referenced announcements may influence the development trajectory of Plinabulin and BeyondSpring’s broader strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BeyondSpring Inc. (Nasdaq: BYSI), a clinical-stage biopharmaceutical company, announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the SEC on April 18, 2023. This report includes audited consolidated financial statements accessible via the SEC and BeyondSpring's website. The company emphasizes its commitment to providing free hard copies of its report to shareholders upon request.
BeyondSpring focuses on developing innovative therapies for patients with high unmet medical needs, leveraging its unique drug discovery platform. Its lead asset, Plinabulin, is under study for various cancer indications, with promising Phase 3 results in combination with chemotherapy to prevent neutropenia and improve survival rates in non-small cell lung cancer. The company also has multiple preclinical immuno-oncology assets.